PD-L1 PET/CT imaging scan for cancer patients
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with or suspected to have cancer (or were treated for cancer before)
- Your doctor has already planned a PD-L1 PET/CT scan for you
- You are able to give written informed consent (or a parent/legal guardian can if you cannot)
- You are not pregnant
- You do not have only non-cancerous growths or lesions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This study tests a new imaging method to see if a special 'tracer' can light up tumors that have a protein called PD-L1, which is a target for immunotherapy. By taking a PET scan, doctors hope to predict whether immunotherapy will work for you.
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Hear when a new PD-L1 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.